About CRISPR Therapeutics AG
CRISPR Therapeutics is a Swiss-American biotechnology company that engages in the development and commercialisation of gene-based therapies. Headquartered in Zug, Switzerland, it was founded in 2012 and also operates research and development facilities in Cambridge, Massachusetts. The company focuses on the fields of cancer treatment, blood disorders and diseases, regenerative medicine such as genetic engineering, and in vivo testing. CRISPR has partaken joint ventures with well-established industry names, such as Bayer and Vertex Pharmaceuticals. Its experimental treatment for sickle cell disease was notably the first CRISPR-based therapy to be approved on humans in the US. CRISPR Therapeutics stock is listed on the Nasdaq stock exchange. Start spread betting or trading CFDs on our CRISPR Therapeutics share price.
Why 300,000 committed global clients† choose CMC
-
Tax-free profits on spread bets. No stamp duty on CFDs^
-
Access to 12,000+ financial instruments
-
99.95%+ platform stability**
-
99.9% fill rate with 0.0029s execution*
-
London-Based Client Support
Constituent weightings
Component |
Weighting |
1 Day |
1 Month |
3 Month |
Trading hours
(shown in London local time )